Clinical

Dataset Information

0

Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer


ABSTRACT: The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as monotherapy (Part I), thereafter in combination with the checkpoint inhibitor pembrolizumab (Part II), in patients with locally advanced primary and recurrent colorectal cancer scheduled to have surgery. Part I will include 4-6 patients and Part II will include up to 10 patients. Part I and Part II are separate and independent sequential components of the study. Patients will only be able to participate in either the Part I cohort or Part II cohort. Main objective of the study is to investigate safety and immune response after TG02-treatment.

DISEASE(S): Colorectal Neoplasms,Rectal Cancer

PROVIDER: 2227548 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2012243 | ecrin-mdr-crc
2008-11-01 | E-MEXP-1803 | biostudies-arrayexpress
2018-05-22 | GSE61298 | GEO
2010-05-16 | E-GEOD-18275 | biostudies-arrayexpress
2014-11-25 | GSE63588 | GEO
2020-09-25 | PXD018178 | Pride
2014-11-27 | GSE63662 | GEO
2009-12-30 | GSE18275 | GEO
2020-01-09 | MODEL1912120003 | BioModels
2017-10-09 | GSE104718 | GEO